GlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas.
Novo Nordisk has taken another step towards expanding beyond its heartlands of diabetes and obesity with a deal to buy US biotech Corvidia Therapeutics and its lead drug for ch
AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, and it stopped a trial of its Farxiga after showing “overwhelming efficacy” in chronic ki
AstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia from chronic kidney disease (CKD), after supportive phase 3 results.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.